PCF Guidelines: Palliative sedation in the imminently dying
... PCF Guidelines: Palliative sedation in the imminently dying Palliative sedation is the intentional drug-induced reduction of consciousness in order to relieve an intolerable refractory symptom. The commonest indications for palliative sedation are delirium and terminal breathlessness. Palliative sed ...
... PCF Guidelines: Palliative sedation in the imminently dying Palliative sedation is the intentional drug-induced reduction of consciousness in order to relieve an intolerable refractory symptom. The commonest indications for palliative sedation are delirium and terminal breathlessness. Palliative sed ...
Thyroid hormones and antithyroid drugs
... • Must be taken at the start of main meals to have maximal effect. • Efficacy will depend on the amount of complex carbohydrates in the meal. • Absence of hypoglycemia when used as monotherapy. • Side effects: gastrointestinal side effects such as flatulence and diarrhea; voglibose, in contrast to a ...
... • Must be taken at the start of main meals to have maximal effect. • Efficacy will depend on the amount of complex carbohydrates in the meal. • Absence of hypoglycemia when used as monotherapy. • Side effects: gastrointestinal side effects such as flatulence and diarrhea; voglibose, in contrast to a ...
spc-doc_PL 20416-0081 - Medicines and Healthcare products
... more frequently with high doses and in predisposed patients. The risk-benefit of haloperidol treatment should be fully assessed before treatment is commenced and patients with risk factors for ventricular arrhythmias such as cardiac disease, family history of sudden death and/or QT prolongation; unc ...
... more frequently with high doses and in predisposed patients. The risk-benefit of haloperidol treatment should be fully assessed before treatment is commenced and patients with risk factors for ventricular arrhythmias such as cardiac disease, family history of sudden death and/or QT prolongation; unc ...
Invega PI
... in three placebo-controlled and active-controlled (olanzapine), 6-week, fixed-dose trials in subjects who met DSM-IV-TR criteria for schizophrenia. The active control was included for assay sensitivity purposes. Efficacy was evaluated using the Positive and Negative Syndrome Scale (PANSS), a validat ...
... in three placebo-controlled and active-controlled (olanzapine), 6-week, fixed-dose trials in subjects who met DSM-IV-TR criteria for schizophrenia. The active control was included for assay sensitivity purposes. Efficacy was evaluated using the Positive and Negative Syndrome Scale (PANSS), a validat ...
Pharmacotherapy of Autism Spectrum Disorders: A Small Piece of
... anterior cingulate cortex and dorso-medial prefrontal cortex ...
... anterior cingulate cortex and dorso-medial prefrontal cortex ...
Abnormally persistent latent inhibition induced by
... and specific for this class of drugs (e.g., Dunn et al., 1993; Killcross et al., 1994; Shadach et al., 2000; Trimble et al., 1997; Weiner and Feldon, 1987; Weiner et al., 1996a, 1997, 2003a,b), it does not differentiate between typical and atypical APDs, limiting considerably the utility of the LI mod ...
... and specific for this class of drugs (e.g., Dunn et al., 1993; Killcross et al., 1994; Shadach et al., 2000; Trimble et al., 1997; Weiner and Feldon, 1987; Weiner et al., 1996a, 1997, 2003a,b), it does not differentiate between typical and atypical APDs, limiting considerably the utility of the LI mod ...
Delirium - Canadian Society of Hospital Pharmacists
... Evidence for routine use of an assessment tool in the ICU3 Evidence suggests anesthesia is not a risk factor4 1 Pun BT et al. Chest. 2007 132(2):624-36 2 Inouye SK,et al. NEJM 1999; 340(9):669-76 3 Devlin J et al Intensive Care Medicine. 2007; 33(6):929-40 4 Bryson GL et al. Canadian Journal of Anae ...
... Evidence for routine use of an assessment tool in the ICU3 Evidence suggests anesthesia is not a risk factor4 1 Pun BT et al. Chest. 2007 132(2):624-36 2 Inouye SK,et al. NEJM 1999; 340(9):669-76 3 Devlin J et al Intensive Care Medicine. 2007; 33(6):929-40 4 Bryson GL et al. Canadian Journal of Anae ...
Treatment issues for psychiatric comorbidities of epilepsy
... in patients with epilepsy and intellectual disabilities are more than insufficient. In the case of antidepressants, SSRIs seem to be safe and effective in this group of patients, even in the presence of autism, but some authors have noted the development of transient treatmentemergent adverse effect ...
... in patients with epilepsy and intellectual disabilities are more than insufficient. In the case of antidepressants, SSRIs seem to be safe and effective in this group of patients, even in the presence of autism, but some authors have noted the development of transient treatmentemergent adverse effect ...
Document
... • Known or suspected QT interval • Major drug interactions • Drugs that may cause QT prolongation • Including antiarrhythmics, opiods antipsychotics, and, diuretics ...
... • Known or suspected QT interval • Major drug interactions • Drugs that may cause QT prolongation • Including antiarrhythmics, opiods antipsychotics, and, diuretics ...
alzheimer disease: treatment of noncognitive behavioral abnormalities
... generally well tolerated in these subjects. However, its cen tral anticholinergic effect likely accounted for subtle decre ments in cognitive function in the imipramine group. The improvement in HAM-D scores was similar to that achieved in the open inpatient studies reported by Greenwald et al. (2 ...
... generally well tolerated in these subjects. However, its cen tral anticholinergic effect likely accounted for subtle decre ments in cognitive function in the imipramine group. The improvement in HAM-D scores was similar to that achieved in the open inpatient studies reported by Greenwald et al. (2 ...
Report of the Psychiatric Drug Safety Expert Advisory Panel
... Panel members were unable to draw any further conclusions on the information provided in this series of case reports. Polypharmacy and concurrent poly-substance use complicated the issue in the majority of these cases. As a result, a connection between the medication and the adverse report could be ...
... Panel members were unable to draw any further conclusions on the information provided in this series of case reports. Polypharmacy and concurrent poly-substance use complicated the issue in the majority of these cases. As a result, a connection between the medication and the adverse report could be ...
Antidepressants in Pregnancy and Breastfeeding
... – This is controversial 0.6% cf 0.06% – some studies dispute this – risk period is 6 - 9 weeks hence avoid during ...
... – This is controversial 0.6% cf 0.06% – some studies dispute this – risk period is 6 - 9 weeks hence avoid during ...
PAROXETINE Paxil NEFAZODONE Serzone
... other SSRIs.165 Like the other SSRIs, it is much safer in overdose than TCAs. Drug Interactions. Paroxetine is a potent inhibitor of CYP2D6, so most other antidepressants, antipsychotics, -blockers, and type Ic antiarrhythmics can have increased serum levels and adverse effects when paroxetine is c ...
... other SSRIs.165 Like the other SSRIs, it is much safer in overdose than TCAs. Drug Interactions. Paroxetine is a potent inhibitor of CYP2D6, so most other antidepressants, antipsychotics, -blockers, and type Ic antiarrhythmics can have increased serum levels and adverse effects when paroxetine is c ...
Omnicare Diabetes Health Management Program
... 1. State an appropriate definition of polypharmacy; 2. Define the term “unnecessary medications” and describe the risks associated with their use; 3. List specific modifiable and non-modifiable risk factors for polypharmacy; 4. Outline approaches and strategies for making drug therapy more appropria ...
... 1. State an appropriate definition of polypharmacy; 2. Define the term “unnecessary medications” and describe the risks associated with their use; 3. List specific modifiable and non-modifiable risk factors for polypharmacy; 4. Outline approaches and strategies for making drug therapy more appropria ...
AGS BEERS Criteria
... n This list is not meant to supersede clinical judgment or an individual patient’s values and needs. Prescribing and managing disease conditions should be individualized and involve shared decision-making. n These criteria also underscore the importance of using a team approach to prescribing and th ...
... n This list is not meant to supersede clinical judgment or an individual patient’s values and needs. Prescribing and managing disease conditions should be individualized and involve shared decision-making. n These criteria also underscore the importance of using a team approach to prescribing and th ...
Pharmacology-Drugs For Parkinson
... Drugs Used for PD a. Levodopa (L-Dopa) i. Most reliable and effective drug used for PD ii. It is the biochemical precursor to dopamine- dopamine cannot cross BBB but levodopa can. iii. Transmitted into brain by amino acid transport systems, gets converted to dopamine and can exert its therapeutic be ...
... Drugs Used for PD a. Levodopa (L-Dopa) i. Most reliable and effective drug used for PD ii. It is the biochemical precursor to dopamine- dopamine cannot cross BBB but levodopa can. iii. Transmitted into brain by amino acid transport systems, gets converted to dopamine and can exert its therapeutic be ...
Psychiatric medications - Mental Illness Fellowship
... of energy, difficulty in concentrating and diminished interest in usually pleasurable activities. It will take a few weeks before noticing any improvement in symptoms although some side effects may be experienced. The medications may need to be taken for some time to improve mood and maintain the im ...
... of energy, difficulty in concentrating and diminished interest in usually pleasurable activities. It will take a few weeks before noticing any improvement in symptoms although some side effects may be experienced. The medications may need to be taken for some time to improve mood and maintain the im ...
Fever development in neuroleptic malignant syndrome during
... NMS and fever and temperatures recorded were above 38°C. Significantly much higher temperatures (39.9°C) were induced by olanzapine (10 mg/d) when taken with valproic acid [65]. Whilst considering the influence of olanzapine in polytherapy, it is worth pointing out that not all patients experienced ...
... NMS and fever and temperatures recorded were above 38°C. Significantly much higher temperatures (39.9°C) were induced by olanzapine (10 mg/d) when taken with valproic acid [65]. Whilst considering the influence of olanzapine in polytherapy, it is worth pointing out that not all patients experienced ...
Agitation in Traumatic Brain Injury
... measurements of agitation (Fugate 1997) Angelino et al (2002) followed Agitated Behavior Scores (ABS) of a 16 yo from coma to wakefulness ABS correlated appropriately both with behavior and with cognitive recovery ...
... measurements of agitation (Fugate 1997) Angelino et al (2002) followed Agitated Behavior Scores (ABS) of a 16 yo from coma to wakefulness ABS correlated appropriately both with behavior and with cognitive recovery ...
Successful Removal of Quetiapine From a Correctional Formulary
... and intravenous16 abuse. The sedative and anxiolytic properties of quetiapine are hypothesized by several authors to be the reason for the drug’s propensity for abuse. Atypical antipsychotics, including quetiapine, have been implicated in causing metabolic derangements associated with diabetes and c ...
... and intravenous16 abuse. The sedative and anxiolytic properties of quetiapine are hypothesized by several authors to be the reason for the drug’s propensity for abuse. Atypical antipsychotics, including quetiapine, have been implicated in causing metabolic derangements associated with diabetes and c ...
Effects of risperidone, amisulpride and nicotine on eye
... Clementz et al. 1995; Lencz et al. 1993), and in psychometric schizotypy (Ettinger et al. 2005; Gooding 1999; Holahan and O’Driscoll 2005; O’Driscoll et al. 1998). Second, several studies have investigated the effects of psychotropic drugs on oculomotor control in healthy volunteers and schizophreni ...
... Clementz et al. 1995; Lencz et al. 1993), and in psychometric schizotypy (Ettinger et al. 2005; Gooding 1999; Holahan and O’Driscoll 2005; O’Driscoll et al. 1998). Second, several studies have investigated the effects of psychotropic drugs on oculomotor control in healthy volunteers and schizophreni ...
Product Information: Lurasidone hydrochloride
... LATUDA film-coated tablets are intended for oral administration only. LATUDA tablets are available in 20 mg (equivalent to 18.62 mg lurasidone), 40 mg (equivalent to 37.24 mg lurasidone), or 80 mg (equivalent to 74.49 mg lurasidone). Lurasidone HCl (active entity) is a white to off-white powder. It ...
... LATUDA film-coated tablets are intended for oral administration only. LATUDA tablets are available in 20 mg (equivalent to 18.62 mg lurasidone), 40 mg (equivalent to 37.24 mg lurasidone), or 80 mg (equivalent to 74.49 mg lurasidone). Lurasidone HCl (active entity) is a white to off-white powder. It ...
SLCO1B1 - PGXL Laboratories
... SLCO1B1 is the gene that makes a liver enzyme called OATP1B1, which helps transport statins medications into the liver more effectively. Roughly 15% of the population possesses the *5 variant, an inherited form of SLOC1B1 which increases risk of statin-induced muscle damage, or myopathy, by 3 to 5 f ...
... SLCO1B1 is the gene that makes a liver enzyme called OATP1B1, which helps transport statins medications into the liver more effectively. Roughly 15% of the population possesses the *5 variant, an inherited form of SLOC1B1 which increases risk of statin-induced muscle damage, or myopathy, by 3 to 5 f ...
Atypical antipsychotic
The atypical antipsychotics (AAP; also known as second generation antipsychotics (SGAs)) are a group of antipsychotic drugs (antipsychotic drugs in general are also known as major tranquilisers and neuroleptics, although the latter is usually reserved for the typical antipsychotics) used to treat psychiatric conditions. Some atypical antipsychotics have received regulatory approval (e.g. by the FDA of the US, the TGA of Australia, the MHRA of the UK) for schizophrenia, bipolar disorder, autism, and as an adjunct in major depressive disorder.Both generations of medication tend to block receptors in the brain's dopamine pathways. Atypicals are less likely – than the most widely-used typical antipsychotic haloperidol – to cause extrapyramidal motor control disabilities in patients such as unsteady Parkinson's disease-type movements, body rigidity, and involuntary tremors. However, only a few of the atypicals have been demonstrated to be superior to lesser-used, low-potency first-generation antipsychotics in this regard.As experience with these agents has grown, several studies have questioned the utility of broadly characterizing antipsychotic drugs as “atypical/second generation"" as opposed to “first generation,” noting that each agent has its own efficacy and side-effect profile. It has been argued that a more nuanced view in which the needs of individual patients are matched to the properties of individual drugs is more appropriate. Although atypical antipsychotics are thought to be safer than typical antipsychotics, they still have severe side effects, including tardive dyskinesia (a serious movement disorder), neuroleptic malignant syndrome, and increased risk of stroke, sudden cardiac death, blood clots, and diabetes. Significant weight gain may also occur. Critics have argued that ""the time has come to abandon the terms first-generation and second-generation antipsychotics, as they do not merit this distinction.""